{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:26:53Z","timestamp":1789576013457,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Project of science and technology of Traditional Chinese Medicine of Zhejiang Province","award":["NO. 2020ZB076, 2022ZB113"],"award-info":[{"award-number":["NO. 2020ZB076, 2022ZB113"]}]},{"name":"\"the Postgraduate Scientific Research Fund\" of Zhejiang Chinese Medical University","award":["2021YKJ03"],"award-info":[{"award-number":["2021YKJ03"]}]},{"name":"the Scientific Research Fund of Zhejiang Provincial Education Department","award":["Y202145970"],"award-info":[{"award-number":["Y202145970"]}]},{"name":"the Key Pilot Program of Integrative Chinese and Western Medicine for Refractoriness Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00520-023-07830-3","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T08:02:30Z","timestamp":1685952150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study"],"prefix":"10.1007","volume":"31","author":[{"given":"Liumei","family":"Shou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijin","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"7830_CR1","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang J, Yan J, Liu B (2018) Targeting VEGF\/VEGFR to modulate antitumor immunity. Front Immunol 9:978","journal-title":"Front Immunol"},{"issue":"4","key":"7830_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13009","volume":"54","author":"G Liu","year":"2021","unstructured":"Liu G, Chen T, Ding Z, Wang Y, Wei Y, Wei X (2021) Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif 54(4):e13009","journal-title":"Cell Prolif"},{"issue":"10043","key":"7830_CR3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jayson","year":"2016","unstructured":"Jayson GC, Kerbel R, Ellis LM, Harris AL (2016) Antiangiogenic therapy in oncology: current status and future directions. Lancet 388(10043):518\u2013529","journal-title":"Lancet"},{"issue":"3","key":"7830_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.jaad.2019.04.021","volume":"83","author":"F Ding","year":"2020","unstructured":"Ding F, Liu B, Wang Y (2020) Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: a meta-analysis of 57 randomized controlled trials involving 24,956 patients. J Am Acad Dermatol 83(3):788\u2013796","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"7830_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112(1):90\u201392","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"4","key":"7830_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40257-016-0197-1","volume":"17","author":"K Chanprapaph","year":"2016","unstructured":"Chanprapaph K, Rutnin S, Vachiramon V (2016) Multikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and management. Am J Clin Dermatol 17(4):387\u2013402","journal-title":"Am J Clin Dermatol"},{"key":"7830_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/978-3-319-90990-5_37","volume-title":"The MASCC Textbook of Cancer Supportive Care and Survivorship","author":"A Freites-Martinez","year":"2018","unstructured":"Freites-Martinez A, Lacouture ME (2018) Dermatologic Adverse Events. In: Olver I (ed) The MASCC Textbook of Cancer Supportive Care and Survivorship. Springer International Publishing, Cham, pp 597\u2013620"},{"issue":"10","key":"7830_CR8","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","volume":"26","author":"B McLellan","year":"2015","unstructured":"McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E (2015) Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 26(10):2017\u20132026","journal-title":"Ann Oncol"},{"issue":"12","key":"7830_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/17512433.2019.1689122","volume":"12","author":"L Ai","year":"2019","unstructured":"Ai L, Xu Z, Yang B, He Q, Luo P (2019) Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. Expert Rev Clin Pharmacol 12(12):1121\u20131127","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"7830_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1634\/theoncologist.2014-0219","volume":"20","author":"RT Anderson","year":"2015","unstructured":"Anderson RT, Keating KN, Doll HA, Camacho F (2015) The hand-foot skin reaction and quality of life questionnaire: an assessment tool for oncology. Oncologist 20(7):831\u2013838","journal-title":"Oncologist"},{"issue":"2","key":"7830_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","volume":"32","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Sibaud V, Gerber PA et al (2021) Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol 32(2):157\u2013170","journal-title":"Ann Oncol"},{"issue":"9","key":"7830_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41422-020-0309-6","volume":"30","author":"P Luo","year":"2020","unstructured":"Luo P, Yan H, Chen X et al (2020) s-HBEGF\/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide. Cell Res 30(9):779\u2013793","journal-title":"Cell Res"},{"issue":"9","key":"7830_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/14728222.2017.1364363","volume":"21","author":"LO Perucci","year":"2017","unstructured":"Perucci LO, Sugimoto MA, Gomes KB, Dusse LM, Teixeira MM, Sousa LP (2017) Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases. Expert Opin Ther Targets 21(9):879\u2013896","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"7830_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-020-00950-x","volume":"13","author":"S Wang","year":"2020","unstructured":"Wang S, Zhang Y (2020) HMGB1 in inflammation and cancer. J Hematol Oncol 13(1):116","journal-title":"J Hematol Oncol"},{"key":"7830_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153541","volume":"85","author":"Q Yang","year":"2021","unstructured":"Yang Q, Zang HM, Xing T et al (2021) Gypenoside XLIX protects against acute kidney injury by suppressing IGFBP7\/IGF1R-mediated programmed cell death and inflammation. Phytomedicine 85:153541","journal-title":"Phytomedicine"},{"issue":"2","key":"7830_CR16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/annonc\/mdt541","volume":"25","author":"N Shinohara","year":"2014","unstructured":"Shinohara N, Nonomura N, Eto M et al (2014) A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. Ann Oncol 25(2):472\u2013476","journal-title":"Ann Oncol"},{"issue":"3","key":"7830_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00280-018-3738-x","volume":"83","author":"BL Melosky","year":"2019","unstructured":"Melosky BL, Lim HJ, Davies JM et al (2019) A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC. Cancer Chemother Pharmacol 83(3):411\u2013417","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"7830_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/onco.13730","volume":"26","author":"A Jatoi","year":"2021","unstructured":"Jatoi A, Ou FS, Ahn DH et al (2021) Preemptive versus reactive topical clobetasol for regorafenib-induced hand-foot reactions: a preplanned analysis of the ReDOS trial. Oncologist 26(7):610\u2013618","journal-title":"Oncologist"},{"key":"7830_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2020.09.012","volume":"140","author":"YS Lee","year":"2020","unstructured":"Lee YS, Jung YK, Kim JH et al (2020) Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: a multicenter, randomised, double-blind controlled study. Eur J Cancer 140:19\u201327","journal-title":"Eur J Cancer"},{"issue":"8","key":"7830_CR20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","volume":"33","author":"Z Ren","year":"2015","unstructured":"Ren Z, Zhu K, Kang H et al (2015) Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33(8):894\u2013900","journal-title":"J Clin Oncol"},{"key":"7830_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/CMAR.S285002","volume":"13","author":"L Shou","year":"2021","unstructured":"Shou L, Shao T, Zhao F, Chen S, Chen Q, Shu Q (2021) The efficacy and safety of the Shouzu Ning Decoction treatment for multi-kinase inhibitors-associated severe hand-foot skin reaction. Cancer Manag Res 13:45\u201353","journal-title":"Cancer Manag Res"},{"key":"7830_CR22","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2147\/OTT.S195635","volume":"12","author":"SJ Yan","year":"2019","unstructured":"Yan SJ, Li Y, Li ZL, Chen Y, Zhang XH, Xiao L (2019) A case report for severe hand-foot skin reaction caused by chemotherapy with actinomycin D in a patient with oculocutaneous albinism. Onco Targets Ther 12:1851\u20131855","journal-title":"Onco Targets Ther"},{"issue":"4","key":"7830_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10238-007-0145-8","volume":"7","author":"C Porta","year":"2007","unstructured":"Porta C, Paglino C, Imarisio I, Bonomi L (2007) Uncovering Pandora\u2019s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 7(4):127\u2013134","journal-title":"Clin Exp Med."},{"issue":"5","key":"7830_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","volume":"161","author":"WJ Lee","year":"2009","unstructured":"Lee WJ, Lee JL, Chang SE et al (2009) Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 161(5):1045\u20131051","journal-title":"Br J Dermatol"},{"issue":"11","key":"7830_CR25","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","volume":"19","author":"ME Lacouture","year":"2008","unstructured":"Lacouture ME, Reilly LM, Gerami P, Guitart J (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19(11):1955\u20131961","journal-title":"Ann Oncol"},{"issue":"3","key":"7830_CR26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","volume":"158","author":"CH Yang","year":"2008","unstructured":"Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC et al (2008) Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 158(3):592\u2013596","journal-title":"Br J Dermatol"},{"issue":"03","key":"7830_CR27","first-page":"298","volume":"43","author":"J Chen","year":"2023","unstructured":"Chen J, Shao T, Zhang Y, Shou L, Shu Q (2023) External application of Shouzuning. Decoction in the treatment of grade 3 hand-foot skin reaction caused by apatinib. Chin J Integr Tradit West Med 43(03):298\u2013302","journal-title":"Chin J Integr Tradit West Med"},{"issue":"9","key":"7830_CR28","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1016\/j.apsb.2021.03.011","volume":"11","author":"Q Lv","year":"2021","unstructured":"Lv Q, Xing Y, Liu J et al (2021) Lonicerin targets EZH2 to alleviate ulcerative colitis by autophagy-mediated NLRP3 inflammasome inactivation. Acta Pharm Sin B 11(9):2880\u20132899","journal-title":"Acta Pharm Sin B"},{"key":"7830_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153285","volume":"77","author":"P Tang","year":"2020","unstructured":"Tang P, Liu H, Lin B et al (2020) Spatholobi Caulis dispensing granule reduces deep vein thrombus burden through antiinflammation via SIRT1 and Nrf2. Phytomedicine 77:153285","journal-title":"Phytomedicine"},{"key":"7830_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.112780","volume":"256","author":"S Shi","year":"2020","unstructured":"Shi S, Liu Z, Xue Z, Chen X, Chu Y (2020) A plasma metabonomics study on the therapeutic effects of the Si-miao-yong-an decoction in hyperlipidemic rats. J Ethnopharmacol 256:112780","journal-title":"J Ethnopharmacol"},{"key":"7830_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.827733","volume":"13","author":"HY Li","year":"2022","unstructured":"Li HY, Sun H, Zhang AH et al (2022) Therapeutic effect and mechanism of Si-Miao-Yong-An-Tang on Thromboangiitis Obliterans based on the urine metabolomics approach. Front Pharmacol 13:827733","journal-title":"Front Pharmacol"},{"issue":"7","key":"7830_CR32","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1111\/jocd.14514","volume":"21","author":"A Treesirichod","year":"2022","unstructured":"Treesirichod A, Chuenboonngarm S, Kritsanaviparkporn C (2022) The efficacy and safety of 20% urea cream and 10% urea cream in the treatment of acanthosis nigricans in adolescents, a randomized comparative double-blind study. J Cosmet Dermatol 21(7):2859\u20132864","journal-title":"J Cosmet Dermatol"},{"key":"7830_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3389\/fimmu.2020.00484","volume":"11","author":"H Yang","year":"2020","unstructured":"Yang H, Wang H, Andersson U (2020) Targeting inflammation driven by HMGB1. Front Immunol 11:484","journal-title":"Front Immunol"},{"issue":"17","key":"7830_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006764","volume":"96","author":"W Zheng","year":"2017","unstructured":"Zheng W, Shi H, Chen Y, Xu Z, Chen J, Jin L (2017) Alteration of serum high-mobility group protein 1 (HMGB1) levels in children with enterovirus 71-induced hand, foot, and mouth disease. Medicine (Baltimore) 96(17):e6764","journal-title":"Medicine (Baltimore)"},{"key":"7830_CR35","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1002\/jcp.30125","volume":"236","author":"J Xue","year":"2021","unstructured":"Xue J, Suarez JS, Minaai M et al (2021) HMGB1 as a therapeutic target in disease. J Cell Physiol 236:3406\u20133419","journal-title":"J Cell Physiol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07830-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07830-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07830-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T10:04:17Z","timestamp":1689329057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07830-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["7830"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07830-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the First Affiliated Hospital of Zhejiang Chinese Medical University (2021\u201310-11 \/ 2021-KL-169\u201301). And the study of patient serum samples was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang Chinese Medical University (2017\u201306-19 \/ 2017-X-046). This study was performed in accordance with the Ethical Standards of the World Medical Association Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This is a retrospective study. The ethics committee of the First Affiliated Hospital of Zhejiang Chinese Medical University has confirmed that it is not necessary to obtain consent. And for 19 patients of blood donors, signed informed consent was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participant provided informed consent for publication of the images in Fig.\u00a0.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"375"}}